NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024

NanoViricides, Inc. NNVC recently announced that it is presenting at Biotech Showcase™ 2024.

Event Information:

This year, registered attendees can view NanoViricides' presentation live, and also access a recorded version after the event. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.

"We are delighted that NanoViricides will be joining us in San Francisco and presenting at Biotech Showcase this year," said Sara Demy, CEO of Demy-Colton. "Biotech Showcase is a prime opportunity for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery."

Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update including the successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies drug products that contain the novel ultra-broad-spectrum antiviral nanomachine active ingredient NV-387.

Image sourced from Shutterstock

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.